MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Sotuletinib

CAS No. : 953769-46-5

MCE 站：Sotuletinib

产品活性：BLZ945 是一种有效，选择性和脑渗透性的 CSF-1R (c-Fms) 抑制剂，IC₅₀ 为 1 nM，选择性是其他受体酪氨酸激酶同系物的 1000 倍。

研究领域：Protein Tyrosine Kinase/RTK

作用靶点：c-Fms

In Vitro: Treatment of bone marrow-derived macrophages (BMDMs) with BLZ945 inhibits CSF-1-dependent proliferation (EC₅₀=67 nM), ａnd decreases CSF-1R phosphorylation, similar to CSF-1R antibody blockade. BLZ945 also reduces viability of CRL-2467 microglia, Ink4a/Arf^−/− BMDMs (PDG genetic background), ａnd NOD/SCID BMDMs. Importantly, BLZ945 treatment in culture does not affect proliferation of any PDG-derived tumor cell lines (all Csf-1r-negative), or U-87 MG human glioma cells, ａnd PDG cell tumor sphere formation is unaffected. Thus, BLZ945 has no direct effects on glioma cells, ａnd perturbs macrophage survival through CSF-1R inhibition.

In Vivo: Mice are treated with BLZ945 or vehicle, ａnd evaluated for symptom-free survival. Median survival in the vehicle-treated cohort is 5.7 weeks. In striking contrast, BLZ945 significantly improves long-term survival with 64.3% surviving to the 26-week trial endpoint. This endpoint is chosen because Ink4a/Arf^−/− mice develop spontaneous tumors, including lymphomas ａnd sarcomas, beginning at ~30 weeks. BLZ945 is well-tolerated over long-term treatment, with no visible side-effects, consistent with histopathological studies. Histological grading revealed high-grade, invasive gliomas in all vehicle-treated mice. By contrast, BLZ945-treated animals have significantly less-malignant tumors, ａnd no detectable lesions in 55.6% of asymptomatic mice at the endpoint. Mice receiving BLZ945 shows reduced CSF1R staining in both cervical tumors ａnd the associated stroma, with a significant decrease in CSF1R⁺ stromal macrophages relative to vehicle-treated mice (P<0.05).

相关产品：Drug Repurposing Compound Library Plus  |  Clinical Compound Library Plus  |  Bioactive Compound Library Plus  |  Kinase Inhibitor Library  |  Protein Tyrosine Kinase Compound Library  |  Anti-Cancer Compound Library  |  Clinical Compound Library  |  CNS-Penetrant Compound Library  |  Drug Repurposing Compound Library  |  Anti-COVID-19 Compound Library  |  Anti-Blood Cancer Compound Library  |  Pexidartinib  |  PLX5622  |  Edicotinib  |  GW2580  |  Pazopanib Hydrochloride  |  Linifanib  |  PRN1371  |  Ki20227  |  PF 477736  |  OSI-930  |  AZD7507  |  c-Fms-IN-1  |  PLX647  |  Vimseltinib  |  cFMS Receptor Inhibitor II  |  CSF1R-IN-1  |  CSF1R-IN-2  |  ARRY-382  |  c-Fms-IN-2  |  c-Fms-IN-3  |  Chiauranib  |  GENZ-882706(Raceme)  |  JTE-952  |  c-Fms-IN-10  |  c-Fms-IN-8  |  c-Fms-IN-9  |  c-Fms-IN-6

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。